|Date||Monday, December 5th , 2022|
|Time||12:30 pm - 1:30 pm|
Our final briefing event for 2022 will take place on December 5th at 12.30pm as an online event.
This event will host Prof Áine Carroll, Chair of the HSE Drugs Board. There will be a significant opportunity for questions from and discussions with Prof Carroll. This will be an online event, questions can be posed through the moderator or asked directly to Prof Carroll.
Joining Prof Carroll will be Brenda Dooley, Founder & CEO with AXIS Healthcare. Brenda will give a high-level outline of AXIS’s recent ISPOR poster regarding the drug reimbursement process in Ireland.
Prof Áine Carroll, Chair of HSE Drugs Group
Áine is Professor of Healthcare Integration and Improvement at University College Dublin, Ireland, and a Consultant in Rehabilitation Medicine at the National Rehabilitation Hospital in Dublin. She is Secretary and Vice-Chair of the International Foundation for Integrated Care (IFIC) and Co-Director of IFIC Ireland along with Chair of the HSE Drugs Group.
Prior to this, she was National Director of the Clinical Strategy and Programmes Division in the Health Services Executive. During her tenure, Professor Carroll established the Integrated Care Programmes for Older Persons, Chronic Disease, Children’s Health, and Patient Flow to promote coordinated care and teamwork across services and specialties, ensuring that care is provided effectively and seamlessly to patients as they move through the system.
Áine is known for her expertise in integrated care, whole system change and implementation. An experienced improvement advisor, she has provided advice, guidance and training on integrated care, improvement and change to leaders of healthcare systems across the world. She is passionate about person-centred coordinated care, complexity theory in healthcare, and the power of stories.
Brenda Dooley, Founder & CEO – AXIS Consulting
Recognising the need for local expertise in reimbursement submissions, Brenda Dooley founded AXIS Consulting over 10 years ago having previously held the role of Market Access Director at Pfizer. As Chief Executive at AXIS, Brenda has led the company to its position as the dominant provider, globally for submissions to the Irish authorities. An expert pricing strategist, Brenda combines her natural flair for problem solving with a genuine interest in helping clients navigate a successful path to reimbursement. AXIS is now on a journey of growth into the UK developing dual HTA submissions to the NCPE and the SMC in Scotland over parallel timelines. The company is also partnering with leading agencies in Austria, Belgium and the Netherlands to develop joint HTA’s for BeNeLuxAI. Brenda is a current member of the Pension and Investment Committee of the University of Galway having previously served on their Audit and Risk Committee.
This event is proudly supported by:
Online bookings are not available or you are logged out.